Sound Income Strategies LLC Buys 21,001 Shares of Pfizer Inc. (NYSE:PFE)

Sound Income Strategies LLC raised its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 9.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 238,438 shares of the biopharmaceutical company’s stock after purchasing an additional 21,001 shares during the quarter. Pfizer accounts for 1.6% of Sound Income Strategies LLC’s portfolio, making the stock its 17th biggest position. Sound Income Strategies LLC’s holdings in Pfizer were worth $12,218,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Moody National Bank Trust Division raised its stake in shares of Pfizer by 0.4% during the fourth quarter. Moody National Bank Trust Division now owns 148,830 shares of the biopharmaceutical company’s stock valued at $7,626,000 after acquiring an additional 653 shares during the last quarter. Enterprise Bank & Trust Co increased its holdings in Pfizer by 11.4% during the 4th quarter. Enterprise Bank & Trust Co now owns 15,135 shares of the biopharmaceutical company’s stock valued at $776,000 after purchasing an additional 1,550 shares during the period. First Citizens Financial Corp lifted its holdings in Pfizer by 2.5% in the 4th quarter. First Citizens Financial Corp now owns 11,647 shares of the biopharmaceutical company’s stock worth $597,000 after buying an additional 288 shares during the period. Accurate Wealth Management LLC grew its position in shares of Pfizer by 24.4% in the 4th quarter. Accurate Wealth Management LLC now owns 22,850 shares of the biopharmaceutical company’s stock worth $1,088,000 after buying an additional 4,479 shares during the last quarter. Finally, Foundations Investment Advisors LLC increased its position in Pfizer by 121.3% during the 4th quarter. Foundations Investment Advisors LLC now owns 72,464 shares of the biopharmaceutical company’s stock valued at $3,713,000 after purchasing an additional 39,719 shares during the period. Institutional investors own 67.62% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $40.10 on Friday. Pfizer Inc. has a 12-month low of $39.23 and a 12-month high of $56.32. The firm has a market capitalization of $225.33 billion, a price-to-earnings ratio of 7.32, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. The firm has a 50 day moving average of $43.26 and a 200 day moving average of $46.03.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The business had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. During the same quarter last year, the company posted $1.08 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 3.3 earnings per share for the current year.

Wall Street Analyst Weigh In

PFE has been the subject of several research analyst reports. Morgan Stanley lowered their price objective on shares of Pfizer from $53.00 to $45.00 and set an “equal weight” rating for the company in a report on Wednesday, February 1st. JPMorgan Chase & Co. set a $45.00 target price on shares of Pfizer in a report on Monday, February 27th. SVB Leerink cut their target price on Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 1st. Wells Fargo & Company dropped their target price on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Friday. Finally, Bank of America downgraded Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 target price on the stock. in a research note on Wednesday, January 4th. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $50.38.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.